Financial & competing interest disclosure
T Harkany and E Keimpema were supported by the Swedish Medical Research Council, Novo Nordisk Foundation, Petrus and Augusta Hedlunds Foundation, the European Commission (‘PAINCAGE’ integrated project) and the National Institutes of Health (DA023214). YL Hurd was supported by the National Institutes of Health (DA023214, DA030359 and DA033660). T Harkany and E Keimpema are in part supported by GW Pharmaceuticals (UK) on a research project unrelated to the subject matter of this editorial. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.